The pharmacology of statins

Pharmacological Research

Volumn 88, Issue , 2014, Pages 3-11

  Sirtori, Cesare R ^a,b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

CYP450; HMG CoA reductase inhibitors; Hypercholesterolemia; LDL receptors; Mycetes; OATP; Statins

Indexed keywords

ABC TRANSPORTER G8; ATORVASTATIN; C REACTIVE PROTEIN; COMPACTIN; CYTOCHROME P450; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ROSUVASTATIN; SIMVASTATIN; SUBTILISIN;

CARDIOVASCULAR DISEASE; CATARACT; CELL TRANSFER; CHOLESTEROL SYNTHESIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESPONSE; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; ENZYME BINDING; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SUBSTRATE; HEART MUSCLE CELL; HEMATURIA; HUMAN; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPOPHILICITY; LIVER TOXICITY; LOW DRUG DOSE; MUSCLE ATROPHY; MYALGIA; MYOPATHY; NEUROLOGIC DISEASE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; ANIMAL; CHEMICALLY INDUCED; MUSCLE DISEASE; TOXIC HEPATITIS;

ANIMALS; DIABETES MELLITUS; DRUG-INDUCED LIVER INJURY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES;

EID: 84906791059     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.03.002     Document Type: Review

References (93)

1. M.S. Brown, and J.L. Goldstein A tribute to Akira Endo, discoverer of a penicillin for cholesterol Ather Suppl 5 2004 13 16
2. A. Endo, M. Kuroda, and K. Tanzawa Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme a reductase by ML-236a and ML-236b fungal metabolites, having hypocholesterolemic activity FEBS Lett 72 1976 323 326 (Pubitemid 8017240)
3. A. Endo, M. Kuroda, and Y. Tsujita Ml-236a, ML-236b, and ML-236c, new inhibitors of cholesterogenesis produced by penicillium citrinium J. Antibiot 29 1976 1346 1348 (Pubitemid 8018023)
4. M. Kuroda, and A. Endo Inhibition of in vitro cholesterol synthesis by fatty acids Biochim Biophys Acta 486 1976 70 81
5. R. Fears, D.H. Richards, and H. Ferres The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-a reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks Atherosclerosis 35 1980 439 449 (Pubitemid 10131096)
6. M.S. Brown, J.R. Faust, J.L. Goldstein, I. Kaneko, and A. Endo Induction of 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in human fibroblasts incubated with compactin (ml-236b), a competitive inhibitor of the reductase J Biol Chem 253 1978 1121 1128 (Pubitemid 8288831)
7. P.T. Kovanen, S.K. Basu, J.L. Goldstein, and M.S. Brown Low density lipoprotein receptors in bovine adrenal cortex. II. Low density lipoprotein binding to membranes prepared from fresh tissue Endocrinology 104 1979 610 616 (Pubitemid 9164333)
8. D.W. Bilheimer, S.M. Grundy, M.S. Brown, and J.L. Goldstein Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes Proc Natl Acad Sci U S A 80 1983 4124 4128
9. R. Uauy, G.L. Vega, S.M. Grundy, and D.M. Bilheimer Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover J Pediatr 113 1988 387 392
10. P.T. Kovanen, D.W. Bilheimer, J.L. Goldstein, J.J. Jaramillo, and M.S. Brown Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog Proc Natl Acad Sci U S A 78 1981 1194 1198 (Pubitemid 11102187)
11. A. Yamamoto, H. Sudo, and A. Endo Therapeutic effects of ML-236b in primary hypercholesterolemia Atherosclerosis 35 1980 259 266 (Pubitemid 10174124)
12. K. Tanzawa, and A. Endo Kinetic analysis of the reaction catalyzed by rat-liver 3-hydroxy-3-methylglutaryl-coenzyme-a reductase using two specific inhibitors Eur J Biochem/FEBS 98 1979 195 201
13. A. Endo Drugs inhibiting HMG-CoA reductase Pharmacol Ther 31 1985 257 267 (Pubitemid 17041770)
14. C.R. Sirtori Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors Pharmacol Res 22 1990 555 563 (Pubitemid 20375361)
15. J.I. Germershausen, V.M. Hunt, R.G. Bostedor, P.J. Bailey, J.D. Karkas, and A.W. Alberts Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo Biochem Biophys Res Commun 158 1989 667 675 (Pubitemid 19075975)
16. Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S) Lancet 344 1994 1383 1389
17. C.R. Sirtori Tissue selectivity of hydroxymethylglutaryl coenzyme a (HMG-CoA) reductase inhibitors Pharmacol Ther 60 1993 431 459 (Pubitemid 24180170)
18. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Begaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414 (Pubitemid 43228152)
19. S. Simpson Case reports of rhabdomyolysis associated with cerivastatin therapy Arch Intern Med 161 2001 2630 2631
20. F.I. Marcus, A.J. Baumgarten, W.L. Fritz, and P.E. Nolan Jr. Alternate-day dosing with statins Am J Med 126 2013 99 104
21. R.A. Parker, B.C. Pearce, R.W. Clark, D.A. Gordon, and J.J. Wright Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme a reductase J Biol Chem 268 1993 11230 11238 (Pubitemid 23162316)
22. W.R. Bensch, T.S. Ingebritsen, and E.R. Diller Lack of correlation between the rate of cholesterol biosynthesis and the activity of 3-hydroxy-3-methylgutaryl coenzyme a reductase in rats and in fibroblasts treated with ML-236b Biochem Biophys Res Commun 82 1978 247 254 (Pubitemid 8347405)
23. R. Puri, S.E. Nissen, P. Libby, M. Shao, C.M. Ballantyne, and P.J. Barter et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy Circulation 128 2013 2395 2403
24. L.C. Hudgins, T.S. Parker, D.M. Levine, B.R. Gordon, S.D. Saal, and X.C. Jiang et al. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers J Lipid Res 44 2003 1489 1498 (Pubitemid 37279593)
25. M.W. Medina, E. Theusch, D. Naidoo, F. Bauzon, K. Stevens, and L.M. Mangravite et al. Rhoa is a modulator of the cholesterol-lowering effects of statin PLoS Genet 8 2012 e1003058
26. T.E. Meigs, D.S. Roseman, and R.D. Simoni Regulation of 3-hydroxy-3-methylglutaryl-coenzyme a reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo J Biol Chem 271 1996 7916 7922 (Pubitemid 26108608)
27. G.L. Vega, C. East, and S.M. Grundy Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia. Effects on kinetics of apolipoprotein b Arteriosclerosis 9 1989 I135 I144
28. S. Lamon-Fava, M.R. Diffenderfer, P.H. Barrett, A. Buchsbaum, N.R. Matthan, and A.H. Lichtenstein et al. Effects of different doses of atorvastatin on human apolipoprotein b-100, b-48, and a-i metabolism J Lipid Res 48 2007 1746 1753 (Pubitemid 47311991)
29. E.M. Ooi, P.H. Barrett, D.C. Chan, P.J. Nestel, and G.F. Watts Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome Atherosclerosis 197 2008 139 146 (Pubitemid 351273233)
30. D.C. Chan, G.F. Watts, P.H. Barrett, I.J. Martins, A.P. James, and J.C. Mamo et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test J Lipid Res 43 2002 706 712 (Pubitemid 34477897)
31. J.C. Hogue, B. Lamarche, Y. Deshaies, A.J. Tremblay, J. Bergeron, and C. Gagne et al. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia Metabolism: Clin Exp 57 2008 246 254
32. D.I. Chasman, F. Giulianini, J. MacFadyen, B.J. Barratt, F. Nyberg, and P.M. Ridker Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER) trial Circ Cardiovasc Genet 5 2012 257 264
33. M. Takemoto, and J.K. Liao Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors Arterioscler Thromb Vasc Biol 21 2001 1712 1719 (Pubitemid 34219772)
34. H.J. Jeong, H.S. Lee, K.S. Kim, Y.K. Kim, D. Yoon, and S.W. Park Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2 J Lipid Res 49 2008 399 409 (Pubitemid 351213625)
35. R. Huijgen, S.M. Boekholdt, B.J. Arsenault, W. Bao, J.M. Davaine, and F. Tabet et al. Plasma pcsk9 levels and clinical outcomes in the tnt (treating to new targets) trial: a nested case-control study J Am Coll Cardiol 59 2012 1778 1784
36. T.A. Miettinen, and H. Gylling Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high ldl cholesterol in a 4s subgroup Atherosclerosis 168 2003 343 349 (Pubitemid 36703334)
37. T.A. Miettinen, H. Gylling, and M.J. Nissinen The role of serum non-cholesterol sterols as surrogate markers of absolute cholesterol synthesis and absorption Nutr Metabol Cardiovasc Dis 21 2011 765 769
38. C.M. Ballantyne, M.A. Blazing, D.B. Hunninghake, M.H. Davidson, Z. Yuan, and P. DeLucca et al. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the comparative hdl efficacy and safety study (CHESS) Am Heart J 146 2003 862 869 (Pubitemid 37378576)
39. M. Marchesi, C. Parolini, S. Caligari, D. Gilio, S. Manzini, and M. Busnelli et al. Rosuvastatin does not affect human apolipoprotein a-i expression in genetically modified mice: a clue to the disputed effect of statins on hdl Br J Pharmacol 164 2011 1460 1468
40. W. de Haan, C.C. van der Hoogt, M. Westerterp, M. Hoekstra, G.M. Dallinga-Thie, and H.M. Princen et al. Atorvastatin increases hdl cholesterol by reducing cetp expression in cholesterol-fed apoe*3-leiden. CEPT mice Atherosclerosis 197 2008 57 63 (Pubitemid 351273273)
41. C.R. Sirtori, G. Mombelli, M. Triolo, and R. Laaksonen Clinical response to statins: mechanism(s) of variable activity and adverse effects Ann Med 44 2012 419 432
42. M. Niemi Transporter pharmacogenetics and statin toxicity Clin Pharmacol Ther 87 2010 130 133
43. K. Bogman, A.K. Peyer, M. Torok, E. Kusters, and J. Drewe HMG-CoA reductase inhibitors and p-glycoprotein modulation Br J Pharmacol 132 2001 1183 1192 (Pubitemid 32234701)
44. M. Fiegenbaum, F.R. da Silveira, C.R. Van der Sand, L.C. Van der Sand, M.E. Ferreira, and R.C. Pires et al. The role of common variants of abcb1, cyp3a4, and cyp3a5 genes in lipid-lowering efficacy and safety of simvastatin treatment Clin Pharmacol Ther 78 2005 551 558 (Pubitemid 41698910)
45. J.A. Hubacek, K.E. Berge, J.C. Cohen, and H.H. Hobbs Mutations in ATP-cassette binding proteins g5 (abcg5) and g8 (abcg8) causing sitosterolemia Hum Mutat 18 2001 359 360
46. J.E. Keskitalo, O. Zolk, M.F. Fromm, K.J. Kurkinen, P.J. Neuvonen, and M. Niemi Abcg2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin Clin Pharmacol Ther 86 2009 197 203
47. S.C. Group, E. Link, S. Parish, J. Armitage, L. Bowman, and S. Heath et al. Slco1b1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 2008 789 799
48. D.F. Carr, H. O'Meara, A.L. Jorgensen, J. Campbell, M. Hobbs, and G. McCann et al. Slco1b1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink Clin Pharmacol Ther 94 2013 695 701
49. M.K. Degorter, R.G. Tirona, U.I. Schwarz, Y.H. Choi, G.K. Dresser, and N. Suskin et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care Circ Cardiovasc Genet 6 2013 400 408
50. L.M. Mangravite, B.E. Engelhardt, M.W. Medina, J.D. Smith, C.D. Brown, and D.I. Chasman et al. A statin-dependent qtl for gatm expression is associated with statin-induced myopathy Nature 502 2013 377 380
51. U. Forstermann, and H. Li Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing enos uncoupling Br J Pharmacol 164 2011 213 223
52. G. Patti, C.P. Cannon, S.A. Murphy, S. Mega, V. Pasceri, and C. Briguori et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies Circulation 123 2011 1622 1632
53. M. Massaro, A. Zampolli, E. Scoditti, M.A. Carluccio, C. Storelli, and A. Distante et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability Cardiovasc Res 86 2010 311 320
54. S. Bellosta, N. Ferri, F. Bernini, R. Paoletti, and A. Corsini Non-lipid-related effects of statins Ann Med 32 2000 164 176 (Pubitemid 30237561)
55. A. Corsini, F. Pazzucconi, P. Pfister, R. Paoletti, and C.R. Sirtori Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin Lancet 348 1996 1584 (Pubitemid 26411662)
56. R. Baetta, M. Camera, C. Comparato, C. Altana, M.D. Ezekowitz, and E. Tremoli Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering Arterioscler Thromb Vasc Biol 22 2002 692 698 (Pubitemid 34408755)
57. P. Duewell, H. Kono, K.J. Rayner, C.M. Sirois, G. Vladimer, and F.G. Bauernfeind et al. Nlrp3 inflammasomes are required for atherogenesis and activated by cholesterol crystals Nature 464 2010 1357 1361
58. J.K. Plenge, T.L. Hernandez, K.M. Weil, P. Poirier, G.K. Grunwald, and S.M. Marcovina et al. Simvastatin lowers c-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction Circulation 106 2002 1447 1452
59. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., and J.J. Kastelein et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein N Engl J Med 359 2008 2195 2207
60. A.R. Pradeep, and M.S. Thorat Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: a randomized clinical trial J Periodontol 81 2010 214 222
61. S. Subramanian, H. Emami, E. Vucic, P. Singh, J. Vijayakumar, and K.M. Fifer et al. High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins J Am Coll Cardiol 62 2013 2382 2391
62. S. Jerwood, and J. Cohen Unexpected antimicrobial effect of statins J Antimicrob Chemother 61 2008 362 364
63. M. Masadeh, N. Mhaidat, K. Alzoubi, S. Al-Azzam, and Z. Alnasser Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin Ann Clin Microbiol Antimicrob 11 2012 13
64. J.N. Thompson, M.M. Huycke, R.A. Greenfield, G. Kurdgelashvili, and C.A. Gentry Case-control study of statin prevention of mould infections Mycoses 54 2011 e481 e485
65. H. Bays Statin safety: an overview and assessment of the data - 2005 Am J Cardiol 97 2006 6C 26C
66. M. Law, and A.R. Rudnicka Statin safety: a systematic review Am J Cardiol 97 2006 52C 60C
67. S.A. Alqahtani, and W. Sanchez Statins are safe for the treatment of hypercholesterolemia in patients with chronic liver disease Gastroenterology 135 2008 702 704
68. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, and R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
69. M. Naples, L.M. Federico, E. Xu, J. Nelken, and K. Adeli Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization Atherosclerosis 198 2008 94 103
70. A.A. Carter, T. Gomes, X. Camacho, D.N. Juurlink, B.R. Shah, and M.M. Mamdani Risk of incident diabetes among patients treated with statins: population based study BMJ 346 2013 f2610
71. C.L. Corpier, P.H. Jones, W.N. Suki, E.D. Lederer, M.A. Quinones, and S.W. Schmidt et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients JAMA: J Am Med Assoc 260 1988 239 241
72. P.S. Phillips, R.H. Haas, S. Bannykh, S. Hathaway, N.L. Gray, and B.J. Kimura et al. Statin-associated myopathy with normal creatine kinase levels Ann Intern Med 137 2002 581 585
73. A. Draeger, K. Monastyrskaya, M. Mohaupt, H. Hoppeler, H. Savolainen, and C. Allemann et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia J Pathol 210 2006 94 102 (Pubitemid 44288185)
74. M.G. Mohaupt, R.H. Karas, E.B. Babiychuk, V. Sanchez-Freire, K. Monastyrskaya, and L. Iyer et al. Association between statin-associated myopathy and skeletal muscle damage CMAJ: Can Med Assoc J journal de l'Association medicale canadienne 181 2009 E11 E18
75. J. Hippisley-Cox, and C. Coupland Individualising the risks of statins in men and women in England and Wales: population-based cohort study Heart 96 2010 939 947
76. S. Pierno, M.P. Didonna, V. Cippone, A. De Luca, M. Pisoni, and A. Frigeri et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study Br J Pharmacol 149 2006 909 919 (Pubitemid 44851715)
77. H. Sinzinger, and J. O'Grady Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems Br J Clin Pharmacol 57 2004 525 528 (Pubitemid 38519660)
78. E. Mas, and T.A. Mori Coenzyme Q(10) and statin myalgia: what is the evidence Curr Atheroscler Rep 12 2010 407 413
79. J. Hanai, P. Cao, P. Tanksale, S. Imamura, E. Koshimizu, and J. Zhao et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity J Clin Invest 117 2007 3940 3951 (Pubitemid 350224103)
80. C. Martini, L. Trapani, L. Narciso, M. Marino, A. Trentalance, and V. Pallottini 3-Hydroxy 3-methylglutaryl coenzyme a reductase increase is essential for rat muscle differentiation J Cell Physiol 220 2009 524 530
81. P.S. Phillips Balancing randomized trials with anecdote Ann Intern Med 150 2009 885 886
82. K.E. Hansen, J.P. Hildebrand, E.E. Ferguson, and J.H. Stein Outcomes in 45 patients with statin-associated myopathy Arch Intern Med 165 2005 2671 2676 (Pubitemid 41785067)
83. R. Agarwal Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 15 2004 2502 2503 (Pubitemid 39159352)
84. J.E. Sidaway, R.G. Davidson, F. McTaggart, T.C. Orton, R.C. Scott, and G.J. Smith et al. Inhibitors of 3-hydroxy-3-methylglutaryl-coa reductase reduce receptor-mediated endocytosis in opossum kidney cells J Am Soc Nephrol 15 2004 2258 2265 (Pubitemid 39159326)
85. S. Bianchi, R. Bigazzi, A. Caiazza, and V.M. Campese A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Am J Kidney Dis 41 2003 565 570 (Pubitemid 36278373)
86. B.A. Golomb Implications of statin adverse effects in the elderly Expert Opin Drug Safe 4 2005 389 397 (Pubitemid 40723714)
87. D.S. King, A.J. Wilburn, M.R. Wofford, T.K. Harrell, B.J. Lindley, and D.W. Jones Cognitive impairment associated with atorvastatin and simvastatin Pharmacotherapy 23 2003 1663 1667 (Pubitemid 37485319)
88. M.J. Summers, K.R. Oliver, J.S. Coombes, and R.G. Fassett Effect of atorvastatin on cognitive function in patients from the lipid lowering and onset of renal disease (LORD) trial Pharmacotherapy 27 2007 183 190 (Pubitemid 46214578)
89. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, and S.M. Cobbe et al. Pravastatin in elderly individuals at risk of vascular disease (prosper): a randomised controlled trial Lancet 360 2002 1623 1630 (Pubitemid 35379733)
90. N.E. Shepardson, G.M. Shankar, and D.J. Selkoe Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations Arch Neurol 68 2011 1385 1392
91. G. Corrao, B. Ibrahim, F. Nicotra, A. Zambon, L. Merlino, and T.S. Pasini et al. Long-term use of statins reduces the risk of hospitalization for dementia Atherosclerosis 230 2013 171 176
92. R.J. Cenedella, J.R. Kuszak, K.J. Al-Ghoul, S. Qin, and P.S. Sexton Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in chbb: Thom rats J Lipid Res 44 2003 198 211 (Pubitemid 36114786)
93. J. Leuschen, E.M. Mortensen, C.R. Frei, E.A. Mansi, V. Panday, and I. Mansi Association of statin use with cataracts: a propensity score-matched analysis JAMA Ophthalmol 2013